We are updating this website
#15 — AUTONOMOUS AI ALZHEIMER’S INSTITUTE (NEW)
Autonomous AI institute purposebuilt to prevent the next 30-year amyloid-cascade detour. Twelve specialized agents under a LeadOrchestrator span genetics, tau, TDP-43, neuroinflammation, synaptic, vascular, glymphatic, metabolic, repurposing, subtype stratification, trial simulation, and regulatory science. A Concept Substitution Detector and Anti-Monoculture Operator algorithmically refuse “remove-plaques ≠ treat-disease” traps and forbid any single mechanism from dominating the hypothesis population at platform scale.
Twelve agents: ad.genetics (Bellenguez 2022 + new GWAS, PRS-CS/LDpred2, MR-Egger/coloc, APOE/TREM2/CLU/PICALM/BIN1/GBA/ABCA7), ad.tau (bepranemab, JNJ-63733657, semorinemab, tau-PET kinetics), ad.tdp43 (LATE-NC, ~30–40% prevalence over 80), MedLink ad.neuroinflammation (AL002 INVOKE-2 PubMed Central re-analysis by TREM2 variant + CSF subtype, NLRP3, sTREM2, YKL-40, GFAP), ad.synaptic, ad.vascular (BBB, glymphatic clearance), ad.glymphatic (TMEM106B, DORA), ad.metabolic (semaglutide EVOKE/EVOKE+, liraglutide ELAD, lithium, metformin), ad.repurposing (rapamycin, spermidine, urolithin A, NR), ad.subtype-stratification (Tijms S1–S5; Nature Murray/Ferreira imaging subtypes; APOE4/4 as genetic AD), National Institutes of Health ad.trial-simulator (PROCOVA virtual controls, surrogate-trap + side-effect-unblinding modeler), ad.regulatory (NIA-AA 2024 AT1T2NISV, FDA Lumipulse 510(k) 16 May 2025, Neurology Live FDA AI 7-step framework, Hogan Lovells FDA-EMA Joint 10 Principles 14 Jan 2026). McGuireWoods Causal Gate (DoWhy + Pearl), Concept-Substitution Detector, Anti-Monoculture Operator, Disease Coverage Score (DCS), Hallmark Scoring Engine for neurodegeneration. Stack: NIM, BioNeMo, MONAI, Clara Imaging (tau-PET, ADNI MRI), Modulus, RAPIDS, Parabricks. Ask: 16× HGX B200 + Clara Imaging co-development.
NVIDIA Technologies Currently Used: NVIDIA NIM, BioNeMo, NeMo Retriever, MONAI, RAPIDS, Parabricks, Triton, CUDA NVIDIA Technologies Being Considered: Clara Imaging (tau-PET / multimodal AT1T2NISV scoring), Modulus (proteostasis PINNs), Omniverse for organoid-on-chip digital twins, GB200 NVL-class training, BioNeMo Blueprints for protein design (anti-tau / anti-TDP-43 / TREM2 agonists), Holoscan Non-NVIDIA Technologies Used: PyTorch, JAX, Neo4j, DoWhy/EconML, PyMC, Stan, scanpy/scverse, AlphaFold3, ESM-3, RFdiffusion, MetaCell IPython, Emulate / MIMETAS organ-on-chip APIs, ADNI / AMP-AD / NACC / DIAN-TU / Knight ADRC / ROSMAP / MSBB / Mount Sinai Brain Bank pipelines, LangGraph, Ray, Weights & Biases, FHIR/OMOP, Snowflake, AWS HealthLake
Datasets Ingested: ADNI, AMP-AD, NACC, large-scale population biobanks, Global Alzheimer’s Association data, DIAN-TU, Knight ADRC, ROSMAP, MSBB, Mount Sinai Brain Bank. Patient-Derived Models: iPSC-derived neurons & cortical organoids, primary microglia, brain-on-chip (Emulate, MIMETAS), patient-derived xenografts where applicable — explicitly framed as a remediation of transgenic-mouse model limitations. Cross-Institute Integration: Tau-propagation biology auto-propagates to #4 Brain Institute as a cognitive-enhancement target. Senolytic candidates from #10 Drug Rescue auto-propagate to ad.neuroinflammation. Anti-tau / anti-TDP-43 / TREM2- agonist binders from #8 Protein Design. Physical-world validation through #14 (organoid screening, patient-iPSC platforms). Funding / Ecosystem Map: ARPA-H CTNEURO (~$30–35M, UCSF-led, cell therapies for neuroinflammation/neurodegeneration); ARPA-H ARPA-H FRONT (Functional Repair of Neocortical Tissue, 2025 launch, iPSC-derived neocortical grafts); DoD CDMRP Alzheimer’s Research Program (FY25 share of the ~$650M CDMRP envelope); ARIA UK neurodegeneration portfolio (Matthew Clifford directorate); VitaDAO + Cerebrum DAO (Cerebrum DAO founded 2024 Cerebrumdao with NEURON-token IP-NFT funding Cerebrumdao for projects on neuroinflammation / protein-fidelity / lysosomal biology / repurposed small molecules); Race Against Dementia (Sir Jackie Stewart); Alzheimer’s Association computational / AI grants.
Structural Epistemic Justification (why this is its own product, not a folder under #4): The April 16, 2026 Cochrane meta-analysis (Nonino et al., 17 trials, Cochrane Library 20,342 participants) AARP confirmed at moderate certainty that antiamyloid mAbs produce no clinically meaningful cognitive benefit Manufacturing Chemist despite plaque clearance; the June 24, 2024 retraction of Lesné et al. (2006 Nature, Aβ*56) PubMed closed a chapter that prolonged the amyloid trajectory by ~16 years and ~$1B+ in misallocated capital. Without a separate, structurally enforced antimonoculture institute, an autonomous platform of CureForge’s scale will reproduce the same concept-substitution failure mode at machine speed. #15 exists to make that failure mode mechanically impossible.
SUBMISSION CHECKLIST
Twelve agents: ad.genetics (Bellenguez 2022 + new GWAS, PRS-CS/LDpred2, MR-Egger/coloc, APOE/TREM2/CLU/PICALM/BIN1/GBA/ABCA7), ad.tau (bepranemab, JNJ-63733657, semorinemab, tau-PET kinetics), ad.tdp43 (LATE-NC, ~30–40% prevalence over 80), MedLink ad.neuroinflammation (AL002 INVOKE-2 PubMed Central re-analysis by TREM2 variant + CSF subtype, NLRP3, sTREM2, YKL-40, GFAP), ad.synaptic, ad.vascular (BBB, glymphatic clearance), ad.glymphatic (TMEM106B, DORA), ad.metabolic (semaglutide EVOKE/EVOKE+, liraglutide ELAD, lithium, metformin), ad.repurposing (rapamycin, spermidine, urolithin A, NR), ad.subtype-stratification (Tijms S1–S5; Nature Murray/Ferreira imaging subtypes; APOE4/4 as genetic AD), National Institutes of Health ad.trial-simulator (PROCOVA virtual controls, surrogate-trap + side-effect-unblinding modeler), ad.regulatory (NIA-AA 2024 AT1T2NISV, FDA Lumipulse 510(k) 16 May 2025, Neurology Live FDA AI 7-step framework, Hogan Lovells FDA-EMA Joint 10 Principles 14 Jan 2026). McGuireWoods Causal Gate (DoWhy + Pearl), Concept-Substitution Detector, Anti-Monoculture Operator, Disease Coverage Score (DCS), Hallmark Scoring Engine for neurodegeneration. Stack: NIM, BioNeMo, MONAI, Clara Imaging (tau-PET, ADNI MRI), Modulus, RAPIDS, Parabricks. Ask: 16× HGX B200 + Clara Imaging co-development.
NVIDIA Technologies Currently Used: NVIDIA NIM, BioNeMo, NeMo Retriever, MONAI, RAPIDS, Parabricks, Triton, CUDA NVIDIA Technologies Being Considered: Clara Imaging (tau-PET / multimodal AT1T2NISV scoring), Modulus (proteostasis PINNs), Omniverse for organoid-on-chip digital twins, GB200 NVL-class training, BioNeMo Blueprints for protein design (anti-tau / anti-TDP-43 / TREM2 agonists), Holoscan Non-NVIDIA Technologies Used: PyTorch, JAX, Neo4j, DoWhy/EconML, PyMC, Stan, scanpy/scverse, AlphaFold3, ESM-3, RFdiffusion, MetaCell IPython, Emulate / MIMETAS organ-on-chip APIs, ADNI / AMP-AD / NACC / DIAN-TU / Knight ADRC / ROSMAP / MSBB / Mount Sinai Brain Bank pipelines, LangGraph, Ray, Weights & Biases, FHIR/OMOP, Snowflake, AWS HealthLake
Datasets Ingested: ADNI, AMP-AD, NACC, large-scale population biobanks, Global Alzheimer’s Association data, DIAN-TU, Knight ADRC, ROSMAP, MSBB, Mount Sinai Brain Bank. Patient-Derived Models: iPSC-derived neurons & cortical organoids, primary microglia, brain-on-chip (Emulate, MIMETAS), patient-derived xenografts where applicable — explicitly framed as a remediation of transgenic-mouse model limitations. Cross-Institute Integration: Tau-propagation biology auto-propagates to #4 Brain Institute as a cognitive-enhancement target. Senolytic candidates from #10 Drug Rescue auto-propagate to ad.neuroinflammation. Anti-tau / anti-TDP-43 / TREM2- agonist binders from #8 Protein Design. Physical-world validation through #14 (organoid screening, patient-iPSC platforms). Funding / Ecosystem Map: ARPA-H CTNEURO (~$30–35M, UCSF-led, cell therapies for neuroinflammation/neurodegeneration); ARPA-H ARPA-H FRONT (Functional Repair of Neocortical Tissue, 2025 launch, iPSC-derived neocortical grafts); DoD CDMRP Alzheimer’s Research Program (FY25 share of the ~$650M CDMRP envelope); ARIA UK neurodegeneration portfolio (Matthew Clifford directorate); VitaDAO + Cerebrum DAO (Cerebrum DAO founded 2024 Cerebrumdao with NEURON-token IP-NFT funding Cerebrumdao for projects on neuroinflammation / protein-fidelity / lysosomal biology / repurposed small molecules); Race Against Dementia (Sir Jackie Stewart); Alzheimer’s Association computational / AI grants.
Structural Epistemic Justification (why this is its own product, not a folder under #4): The April 16, 2026 Cochrane meta-analysis (Nonino et al., 17 trials, Cochrane Library 20,342 participants) AARP confirmed at moderate certainty that antiamyloid mAbs produce no clinically meaningful cognitive benefit Manufacturing Chemist despite plaque clearance; the June 24, 2024 retraction of Lesné et al. (2006 Nature, Aβ*56) PubMed closed a chapter that prolonged the amyloid trajectory by ~16 years and ~$1B+ in misallocated capital. Without a separate, structurally enforced antimonoculture institute, an autonomous platform of CureForge’s scale will reproduce the same concept-substitution failure mode at machine speed. #15 exists to make that failure mode mechanically impossible.
SUBMISSION CHECKLIST
Recommended order of submission:
1. #15 Alzheimer’s Institute — submit FIRST. It carries the strongest current-events anchor: Cochrane (16 Apr 2026), Lesné retraction (24 Jun 2024), Fujirebio Lumipulse 510(k) (16 May 2025, PPV ~92% / NPV ~97%; MedTech Dive Labcorp launch Aug 2025; Quest launch Jul 2025), NIA-AA 2024 AT1T2NISV revision, EMA lecanemab restriction ALZFORUM to APOE4 non-carriers/heterozygotes Eisai (7 Apr 2025), ALZFORUM NICE rejection (19 Jun 2025), The Pharmaceutical Journal Nationalhealthexecutive FDA AI 7-step credibility framework (6 Jan 2025), FDA and FDA-EMA Joint 10 Guiding Principles (14 Jan 2026). McGuireWoods Strongest opener for NVIDIA Healthcare & Life Sciences, ARPA-H (CT-NEURO and FRONT), DoD CDMRP, and ARIA UK direct outreach.
2. #1 Master Platform → #2 Flight Simulator → #13 ABE-OS → #14 Physical World (the platform spine).
3. #3 Core Longevity → #4 Brain (re-anchored) → #5 Cardiac → #6 78-Organ.
4. #7 NaFM → #8 Protein Design → #9 Animal Longevity → #10 Drug Rescue.
5. #11 Cryonics → #12 Governance/Safety.
Co-pitch angles (revised):
A. Discovery Stack: #1 + #2 + #7 + #8 — for NVIDIA BioNeMo Blueprints partnership.
B. Clinical Translation Stack: #10 + #14 + #6 — for FDA AI credibility framework + Clara Imaging.
C. Autonomous Operator Stack: #1 + #13 + #12 — for NVIDIA Enterprise + AI Safety teams.
D. NEURO STACK (new): #15 Alzheimer’s + #4 Brain + #14 Physical World — for NVIDIA Healthcare BD plus joint outreach to ARPA-H CT-NEURO / FRONT, DoD CDMRP, and ARIA UK. The pitch: a closed-loop, anti-monoculture neuro discovery+device platform that lets multiple non-amyloid mechanisms (tau, TDP-43, glymphatic, vascular, metabolic, microglial) be tested in patient-iPSC and organoid systems with credibility-framework-aligned trial simulation, and that reads out into BCI-mediated cognitive-enhancement targets through #4.
Specific NVIDIA teams to engage (revised):
1. #15 Alzheimer’s Institute — submit FIRST. It carries the strongest current-events anchor: Cochrane (16 Apr 2026), Lesné retraction (24 Jun 2024), Fujirebio Lumipulse 510(k) (16 May 2025, PPV ~92% / NPV ~97%; MedTech Dive Labcorp launch Aug 2025; Quest launch Jul 2025), NIA-AA 2024 AT1T2NISV revision, EMA lecanemab restriction ALZFORUM to APOE4 non-carriers/heterozygotes Eisai (7 Apr 2025), ALZFORUM NICE rejection (19 Jun 2025), The Pharmaceutical Journal Nationalhealthexecutive FDA AI 7-step credibility framework (6 Jan 2025), FDA and FDA-EMA Joint 10 Guiding Principles (14 Jan 2026). McGuireWoods Strongest opener for NVIDIA Healthcare & Life Sciences, ARPA-H (CT-NEURO and FRONT), DoD CDMRP, and ARIA UK direct outreach.
2. #1 Master Platform → #2 Flight Simulator → #13 ABE-OS → #14 Physical World (the platform spine).
3. #3 Core Longevity → #4 Brain (re-anchored) → #5 Cardiac → #6 78-Organ.
4. #7 NaFM → #8 Protein Design → #9 Animal Longevity → #10 Drug Rescue.
5. #11 Cryonics → #12 Governance/Safety.
Co-pitch angles (revised):
A. Discovery Stack: #1 + #2 + #7 + #8 — for NVIDIA BioNeMo Blueprints partnership.
B. Clinical Translation Stack: #10 + #14 + #6 — for FDA AI credibility framework + Clara Imaging.
C. Autonomous Operator Stack: #1 + #13 + #12 — for NVIDIA Enterprise + AI Safety teams.
D. NEURO STACK (new): #15 Alzheimer’s + #4 Brain + #14 Physical World — for NVIDIA Healthcare BD plus joint outreach to ARPA-H CT-NEURO / FRONT, DoD CDMRP, and ARIA UK. The pitch: a closed-loop, anti-monoculture neuro discovery+device platform that lets multiple non-amyloid mechanisms (tau, TDP-43, glymphatic, vascular, metabolic, microglial) be tested in patient-iPSC and organoid systems with credibility-framework-aligned trial simulation, and that reads out into BCI-mediated cognitive-enhancement targets through #4.
Specific NVIDIA teams to engage (revised):
- NVIDIA Healthcare & Life Sciences (BioNeMo, NIM, Parabricks)
- NVIDIA Clara Imaging team (NEW for #15: tau-PET, ADNI MRI, multimodal AT1T2NISV scoring; also relevant for #4, #5, #6)
- NVIDIA Modulus / Physics-ML (electrodes, tissue, proteostasis PINNs)
- NVIDIA Omniverse / Isaac Sim (digital twins, organoid platforms, surgical planning for #4)
- NVIDIA Holoscan (real-time clinical edge)
- NVIDIA Inception Capital Connect + co-marketing
- NVIDIA AI Safety / Trustworthy AI (for #12 and #15 Concept Substitution Detector)
- NVIDIA Federal / Public Sector (for ARPA-H, DoD CDMRP, ARIA pathways)